Axsome Therapeutics, Inc (AXSM) — Analysis Summary
Axsome Therapeutics, Inc (AXSM) has a market cap of $11.22B with year-over-year revenue growth of +65.5%. Net margin stands at -28.7%. The stock trades at a P/E ratio of -59.6.
Key Takeaways
- Revenue changed +65.5% year-over-year
- Net margin of -28.7%
- P/E ratio of -59.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, AXSM posted revenue growth of +65.5% and trades at a P/E of -59.6.
Axsome Therapeutics, Inc (AXSM)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -12.6x — earnings do not cover interest payments
D/E at 3.4x — high financial leverage
Operating margin at -24.4% — material operating losses
Net margin at -26.6% — significant losses
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
925
Headquarters
NEW YORK, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.